Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Oxybutynin chloride · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | Oxybutynin chloride 15 mg once daily for 12 weeks |
| 002 | PLACEBO_COMPARATOR | Placebo Once daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Once daily for 12 weeks |
| Oxybutynin chloride | DRUG | 15 mg once daily for 12 weeks |
Inclusion Criteria: * Patients must be in good health * Must be naturally postmenopausal and have not experienced menses for at least 6 months prior to the start of the study * Must have serum FSH levels \> 40 mIU/mL * Must average seven or more moderate to severe hot flushes with sweating per day,...
Oxybutynin chloride is being studied for the treatment of vasomotor symptoms, such as hot flashes, in healthy post-menopausal women. It is an investigational use for this small molecule, which is also known for other indications. The Phase 2 trial NCT00990886 evaluated its effect on these symptoms in women aged 40 years and older.
Oxybutynin chloride targets the muscarinic acetylcholine receptors CHRM2 and CHRM3. It acts as an antagonist at these receptors, blocking acetylcholine signaling. This mechanism is relevant to its investigational use for menopause-related vasomotor symptoms.
Johnson & Johnson, ticker JNJ, is the developer of oxybutynin chloride for menopause. The company is responsible for the clinical development program in this indication.
Oxybutynin chloride is in Phase 2 development for menopause. It is investigational and has not been approved for this indication. The Phase 2 trial has been completed.
Oxybutynin chloride has been studied in one completed Phase 2 trial, NCT00990886, titled 'The Effect of Extended-Release Oxybutynin Chloride on Vasomotor Symptoms in Healthy Post-Menopausal Women.' The trial enrolled 148 participants, was randomized, double-blind, and placebo-controlled, and included women aged 40 years and older.